

June 29, 2020

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
--	--

Dear Sirs,

**Sub: Disclosure of Related Party Transactions for the half year ended 31<sup>st</sup> March 2020.**  
**Ref: Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended 31<sup>st</sup> March 2020.

Please take the information on record.

Thanking you,

**Yours faithfully,**  
**For AUROBINDO PHARMA LIMITED**

  
**B Adi Reddy**  
**Company Secretary**



Encl: as above.

**AUROBINDO PHARMA LIMITED**

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038. T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

[www.aurobindo.com](http://www.aurobindo.com)

1) Names of related parties and description of relationship

a) Joint ventures

Novagen Pharma (Pty) Limited, South Africa (Joint Venture of a step-down subsidiary, Aurogen South Africa (Pty) Ltd, South Africa)  
 Eugia Pharma Specialities Limited, India (Joint venture of a subsidiary, Curepro Parenterals Limited, India)  
 Tergene Biotech Private Limited, India  
 Raidurgam Developers Limited, India (formerly known as Aurobindo Antibiotics limited, India)  
 Purple Bellflower (Pty)Ltd, South Africa (w.e.f. 23 August 2018) (Joint Venture of a step-down subsidiary, Aurogen South Africa (Pty) Ltd, South Africa)  
 Luoxin Aurovitas Pharm (Chengdu) Co. Ltd. (w.e.f. 25 March 2019) (Joint Venture of a subsidiary, Helix Healthcare B.V., The Netherlands)  
 Longxiang Pharma Taizhou Co. Ltd. (w.e.f. 20 October 2019) (Joint Venture of a subsidiary, Helix Healthcare B.V., The Netherlands)  
 Novagen BBBEE Invest Co (Pty) Ltd (w.e.f. 7 November, 2019) (Joint Venture of a step-down subsidiary, Aurogen South Africa (Pty) Ltd, South Africa)

b) Enterprises over which key management personnel or their relatives exercise significant influence

Pravasha Industries Private Limited, India  
 Sri Sai Packaging, India (Partnership firm)  
 Trident Chemphar Limited, India  
 Axis Clinicals Limited, India  
 Pranit Packaging Private Limited, India  
 SGD Pharma India Limited (formerly Cogent Glass Limited), India  
 Orem Access Bio Inc, India  
 Veritaz Healthcare Limited, India  
 Axis Clinicals LLC, USA  
 Crest Cellulose Private Limited, India  
 East Pharma Technologies, India (Partnership firm)  
 Axis Clinicals Latina SA DE CV, Mexico  
 Gelcaps Industries, India  
 Aurobindo Foundation, India  
 Giyaan Pharma Private Limited, India  
 Alcedo Pharmachem Private Limited, India  
 Ambipack Industries, India

c) Key managerial personnel

Mr. K. Nityananda Reddy, Whole-time Director  
 Dr. M. Sivakumar, Whole-time Director  
 Mr. M. Madan Mohan Reddy, Whole-time Director  
 Mr. P. Sarath Chandra Reddy, Whole-time Director  
 Mr. N. Govindarajan, Managing Director  
 Mr. Santhanam Subramanian, Chief Financial Officer  
 Mr. B. Adi Reddy, Company Secretary  
 Mr. K. Ragunathan, Non-executive Chairman and Independent Director  
 Mr. M. Sitarama Murty, Independent Director  
 Dr. (Mrs.) Avnit Bimal Singh, Independent Director  
 Mr.P.Venkata Ramprasad Reddy, Non Executive promoter director  
 Mrs.Savitha Mahajan, Independent Director

d) Relatives to key managerial personnel

Mr. Vishnu M Sriram (Son in law of Dr. M. Sivakumar, Wholetime Director)

ii) Transactions with related parties

a. Transactions with joint ventures

	Half Year ended 31 March 2020
<b>Raidurgam Developers Limited</b>	
Investment in optionally convertible debentures	266.0
Interest accrued	18.2
<b>Novagen Pharma (Pty) Limited, South Africa</b>	
Sale of products	57.3
Sale of services	16.5
Dividend received	0.4
<b>Purple Bell Flower (Pty) Limited, South Africa</b>	
Dividend received	2.7
Dividend paid	5.5
<b>Eugia Pharma Specialities Ltd, India</b>	
Sale of products	6.5
Purchases	181.3
Purchase of property, plant and equipment	0.2
<b>Tergene Biotech Pvt. Ltd, India</b>	
Investment in 10.5% Cumulative Redeemable Preference shares	24.0



**Aurobindo Pharma Limited**

Disclosure of related party transactions on a consolidated basis for the half year ended 31 March 2020

(All amounts are in Indian Rupees in millions)

**b. Transactions with enterprises over which key management personnel or their relatives exercise significant influence**

Half Year ended  
31 March 2020

<b>Pravesha Industries Private Limited, India</b>	
Purchases	1,594.2
Sale of property, plant and equipment	0.4
<b>Sri Sai Packaging, India</b>	
Sale of products	0.2
Purchases	126.5
<b>Axis Clinicals Limited, India</b>	
Purchase of services	561.1
Purchase of Fixed assets	0.9
<b>Axls Clinicals LLC, USA</b>	
Purchase of services	216.6
Purchase of Fixed Assets	-
<b>Axls Clinicals Latina SA DE CV, Mexico</b>	
Purchase of services	25.3
<b>Trident Chemphar Limited, India</b>	
Purchases	799.2
Purchase of services	32.5
<b>Pranit Packaging Private Limited, India</b>	
Purchases	123.3
<b>SGD Pharma India Limited (formerly Cogent Glass Limited), India</b>	
Purchases	621.0
Purchase of services	3.9
<b>Orem Access Bio Inc, India</b>	
Purchases	172.5
<b>Veritaz Healthcare Limited, India</b>	
Sale of products	122.7
Rent received	0.1
<b>Crest Cellulose Private limited, India</b>	
Purchases	138.1
<b>East Pharma Technologies, India</b>	
Purchases	58.8
<b>Geleaps Industries, India</b>	
Purchases	232.6
<b>Aurobindo Foundation, India</b>	
Contribution towards CSR activities	401.1
<b>Glyaan Pharma Private Limited, India</b>	
Sale of products	8.4
<b>Alcedo Pharmachem Private Limited, India</b>	
Purchases	122.5
<b>Ambipack Industries, India</b>	
Purchases	74.3

**c. Transactions with key managerial personnel or their relatives**

Half Year ended  
31 March 2020

<b>Mr. K Nityananda Reddy</b>	
Managerial remuneration	8.4
Rent expense	1.3
<b>Dr. M Sivakumaran</b>	
Managerial remuneration	8.4
<b>Mr. M Madan Mohan Reddy</b>	
Managerial remuneration	22.3
<b>Mr. P Sarath Chandra Reddy</b>	
Managerial remuneration	4.9
<b>Mr. Vishnu M Sriram</b>	
Remuneration	3.4
<b>Mr.N Govindarajan</b>	
Managerial Remuneration	137.5
<b>Mr.Santhanam Subramanian</b>	
Remuneration	11.5
<b>Mr.B. Adl Reddy</b>	
Remuneration	2.7
<b>Mr. P.Venkata Ramaprasad Reddy</b>	
Director sitting fees	0.2
<b>Mr. K.Ragunathan, Non-executive Chairman and Independent Director</b>	
Director sitting fees	0.6
<b>Mr. M. Sitarama Murty, Independent Director</b>	
Director sitting fees	0.5
<b>Mrs.Avni Bimal Singh, Independent Director</b>	
Director sitting fees	0.3
<b>Mrs.Savitha Mahajan, Independent Director</b>	
Director sitting fees	0.5

Note:

Managerial remuneration does not include provision for gratuity and leave encashment, which is determined for the Company as a whole.



**Aurobindo Pharma Limited**

Disclosure of related party transactions on a consolidated basis for the half year ended 31 March 2020

(All amounts are in Indian Rupees in millions)

## iii) Closing balances of related parties

## a. Balances with Joint ventures at the year end

As at 31 March 2020

Novagen Pharma (Pty) Limited, South Africa	
Balance receivable	52.2
Purple Bell Flower (Pty) Limited, South Africa	
Balance payable	4.9
Raidurgam Developers Limited, India	
Balance receivable	14.4
Eugia Pharma Specialities Limited, India	
Balance payable	85.2

## b. Balances with enterprises over which key management personnel or their relatives exercise significant influence at the year end.

As at 31 March 2020

Pravasha Industries Private Limited, India	
Balance payable	994.9
Sri Sai Packaging, India	
Balance payable	3.7
Axis Clinicals Limited, India	
Balance payable	209.4
Trident Chemphar Limited, India	
Balance receivable	738.8
Balance payable	1.9
Pranit Packaging Private Limited, India	
Balance receivable	0.9
Balance payable	16.1
SGD Pharma India Limited (formerly Cogent Glass Limited), India	
Balance payable	402.9
Veritaz Healthcare Limited, India	
Balance receivable	120.7
Orem Access Bio Inc, India	
Balance payable	86.3
Crest Cellulose Private Limited, India	
Balance payable	88.0
East Pharma Technologies, India	
Balance payable	17.4
Gelcaps Industries, India	
Balance payable	91.3
Axis Clinicals LLC, USA	
Balance receivable	12.8
Balance payable	3.3
Axis Clinicals Latna SA DE CV, Mexico	
Balance payable	23.4
Glyaan Pharma Private Limited, India	
Balance receivable	8.3
Alcedo Pharmachem Private Limited, India	
Balance payable	7.0
Ambipack Industries, India	
Balance payable	21.5

## c. Balances with with key managerial personnel at the year end

As at 31 March 2020

Mr.N Govindarajan	
Balance payable	100.0
Mr. K Nityananda Reddy	
Balance payable	0.2

